Skip to main content

Table 5 Summary of dichotomous outcomes for sildenafil

From: Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction

  

Number of

Percent with

  

Outcome

Dose (mg)

Trials

Patients

Sildenafil

Placebo

Relative benefit or risk (95% CI)

NNT/NNTp/NNH (95% CI)

Efficacy

Improved erections

25

5

778

68

27

2.5 (2.1 to 3.0)

2.4 (2.1 to 2.9)

 

50

5

781

80

27

3.0 (2.5 to 3.5)

1.9 (1.7 to 2.1)

 

100

26

5000

76

23

3.4 (3.1 to 3.6)

1.9 (1.8 to 2.0)

 

50/100

29

5467

76

23

3.3 (3.1 to 3.5)

1.9 (1.8 to 2.0)

Withdrawal

All-cause

25

3

522

11

14

0.9 (0.6 to 1.4)

not calculated

 

50

4

560

10

14

0.7 (0.4 to 1.2)

not calculated

 

100

27

5219

7.8

12

0.6 (0.5 to 0.8)

22 (16 to 34)

 

50/100

30

5562

8.0

12

0.7 (0.6 to 0.8)

23 (17 to 37)

Lack of efficacy

25

3

522

3.0

3.7

0.9 (0.3 to 2.5)

not calculated

 

50

3

526

1.8

3.5

0.6 (0.2 to 1.9)

not calculated

 

100

27

5119

1.1

4.5

0.3 (0.2 to 0.4)

24 (20 to 32)

 

50/100

30

5463

1.2

4.4

0.3 (0.2 to 0.4)

25 (21 to 34)

Adverse event

25

4

777

1.5

1.3

1.0 (0.4 to 3.0)

not calculated

 

50

5

819

1.6

1.2

1.7 (0.7 to 4.4)

not calculated

 

100

28

5311

1.4

0.6

1.8 (1.1 to 2.7)

120 (66 to 520)

 

50/100

31

5787

1.6

0.6

1.7 (1.1 to 2.6)

120 (67 to 560)

Adverse events

All cause

50/100

18

2852

50

30

1.6 (1.5 to 1.8)

4.9 (4.2 to 6.0)

Serious

50/100

17

2591

2.5

2.4

1.1 (0.6 to 1.7)

not calculated

Headache

50/100

34

6386

17

5.2

3.3 (2.8 to 3.9)

8.6 (7.6 to 10)

Dyspepsia

50/100

26

4967

7.8

2.3

3.3 (2.5 to 4.4)

18 (15 to 23)

Flushing

50/100

33

6363

13

1.9

6.7 (5.2 to 8.7)

9.0 (8.1 to 10)

Rhinitis

50/100

21

4283

5.4

2.1

2.5 (1.8 to 3.5)

31 (23 to 47)

  1. NNT is given in standard font, NNTp in bold, and NNH in bold italic. No NNT/NNTp/NNH was calculated unless there was a statistically significant difference